Noninvasive Diagnosis of Secondary Infections in COVID-19 by Sequencing of Plasma Microbial Cell-Free DNA

Grace Lisius,Radha Duttagupta,Asim A. Ahmed,Matthew Hensley,Nameer Al-Yousif,Michael Lu,William Bain,Faraaz Shah,Timothy A. Blauwkamp,Sivan Bercovici,Caitlin Schaefer,Shulin Qin,Xiaohong Wang,Yingze Zhang,Kevin J. Mitchell,Ellen K. Hughes,Jana L. Jacobs,Asma Naqvi,Ghady Haidar,John W. Mellors,Barbara Methe,Bryan J. Mcverry,Alison Morris,Georgios D. Kitsios
DOI: https://doi.org/10.1016/j.isci.2023.108093
IF: 5.8
2023-01-01
iScience
Abstract:Secondary infection (SI) diagnosis in severe COVID-19 remains challenging. We correlated metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA-Seq) with clinical SI assessment, immune response, and outcomes. We classified 42 COVID-19 inpatients as microbiologically confirmed-SI (Micro-SI, n = 8), clinically diagnosed-SI (Clinical-SI, n = 13, i.e., empiric antimicrobials), or no-clinical-suspicion-for-SI (No-Suspected-SI, n = 21). McfDNA-Seq was successful in 73% of samples. McfDNA detection was higher in Micro-SI (94%) compared to Clinical-SI (57%, p = 0.03), and unexpectedly high in No-Suspected-SI (83%), similar to Micro-SI. We detected culture-concordant mcfDNA species in 81% of Micro-SI samples. McfDNA correlated with LRT 16S rRNA bacterial burden (r = 0.74, p = 0.02), and biomarkers (white blood cell count, IL-6, IL-8, SPD, all p < 0.05). McfDNA levels were predictive of worse 90-day survival (hazard ratio 1.30 [1.02-1.64] for each log(10) mcfDNA, p = 0.03). High mcfDNA levels in COVID-19 patients without clinical SI suspicion may suggest SI under-diagnosis. McfDNA-Seq offers a non-invasive diagnostic tool for pathogen identification, with prognostic value on clinical outcomes.
What problem does this paper attempt to address?